JPWO2022069690A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022069690A5 JPWO2022069690A5 JP2023519831A JP2023519831A JPWO2022069690A5 JP WO2022069690 A5 JPWO2022069690 A5 JP WO2022069690A5 JP 2023519831 A JP2023519831 A JP 2023519831A JP 2023519831 A JP2023519831 A JP 2023519831A JP WO2022069690 A5 JPWO2022069690 A5 JP WO2022069690A5
- Authority
- JP
- Japan
- Prior art keywords
- disorder
- unsubstituted
- pharmaceutical composition
- use according
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 24
- 239000000380 hallucinogen Substances 0.000 claims 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 12
- 208000035475 disorder Diseases 0.000 claims 12
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 8
- 239000001301 oxygen Substances 0.000 claims 8
- 229910052760 oxygen Inorganic materials 0.000 claims 8
- 239000001307 helium Substances 0.000 claims 7
- 229910052734 helium Inorganic materials 0.000 claims 7
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 6
- 125000003107 substituted aryl group Chemical group 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 claims 4
- 239000000443 aerosol Substances 0.000 claims 4
- 210000003169 central nervous system Anatomy 0.000 claims 4
- 239000006199 nebulizer Substances 0.000 claims 4
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 3
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 3
- 229910052805 deuterium Inorganic materials 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 3
- 150000002431 hydrogen Chemical class 0.000 claims 3
- 208000024714 major depressive disease Diseases 0.000 claims 3
- 239000000843 powder Substances 0.000 claims 3
- 125000005017 substituted alkenyl group Chemical group 0.000 claims 3
- 125000000547 substituted alkyl group Chemical group 0.000 claims 3
- 125000004426 substituted alkynyl group Chemical group 0.000 claims 3
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 3
- ZSTKHSQDNIGFLM-UHFFFAOYSA-N 5-methoxy-N,N-dimethyltryptamine Chemical compound COC1=CC=C2NC=C(CCN(C)C)C2=C1 ZSTKHSQDNIGFLM-UHFFFAOYSA-N 0.000 claims 2
- 208000011688 Generalised anxiety disease Diseases 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 claims 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims 2
- 239000007789 gas Substances 0.000 claims 2
- 208000029364 generalized anxiety disease Diseases 0.000 claims 2
- 238000002663 nebulization Methods 0.000 claims 2
- 239000001272 nitrous oxide Substances 0.000 claims 2
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 2
- 238000002203 pretreatment Methods 0.000 claims 2
- 230000001568 sexual effect Effects 0.000 claims 2
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 claims 1
- 208000007848 Alcoholism Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000000103 Anorexia Nervosa Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 206010006550 Bulimia nervosa Diseases 0.000 claims 1
- 208000027691 Conduct disease Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 208000001613 Gambling Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- DMULVCHRPCFFGV-UHFFFAOYSA-N N,N-dimethyltryptamine Chemical compound C1=CC=C2C(CCN(C)C)=CNC2=C1 DMULVCHRPCFFGV-UHFFFAOYSA-N 0.000 claims 1
- 208000026251 Opioid-Related disease Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 206010033888 Paraphilia Diseases 0.000 claims 1
- SPCIYGNTAMCTRO-UHFFFAOYSA-N Psilocine Natural products C1=CC(O)=C2C(CCN(C)C)=CNC2=C1 SPCIYGNTAMCTRO-UHFFFAOYSA-N 0.000 claims 1
- QVDSEJDULKLHCG-UHFFFAOYSA-N Psilocybine Natural products C1=CC(OP(O)(O)=O)=C2C(CCN(C)C)=CNC2=C1 QVDSEJDULKLHCG-UHFFFAOYSA-N 0.000 claims 1
- 201000001880 Sexual dysfunction Diseases 0.000 claims 1
- 206010041250 Social phobia Diseases 0.000 claims 1
- 206010042458 Suicidal ideation Diseases 0.000 claims 1
- 206010042464 Suicide attempt Diseases 0.000 claims 1
- 208000025569 Tobacco Use disease Diseases 0.000 claims 1
- 238000010521 absorption reaction Methods 0.000 claims 1
- 208000025746 alcohol use disease Diseases 0.000 claims 1
- 229940025084 amphetamine Drugs 0.000 claims 1
- 208000022531 anorexia Diseases 0.000 claims 1
- 238000000889 atomisation Methods 0.000 claims 1
- 208000025748 atypical depressive disease Diseases 0.000 claims 1
- 208000014679 binge eating disease Diseases 0.000 claims 1
- 208000028683 bipolar I disease Diseases 0.000 claims 1
- 208000022257 bipolar II disease Diseases 0.000 claims 1
- VTTONGPRPXSUTJ-UHFFFAOYSA-N bufotenin Chemical compound C1=C(O)C=C2C(CCN(C)C)=CNC2=C1 VTTONGPRPXSUTJ-UHFFFAOYSA-N 0.000 claims 1
- 208000015114 central nervous system disease Diseases 0.000 claims 1
- 229960003920 cocaine Drugs 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 208000026725 cyclothymic disease Diseases 0.000 claims 1
- 206010061428 decreased appetite Diseases 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 229940112141 dry powder inhaler Drugs 0.000 claims 1
- 208000024732 dysthymic disease Diseases 0.000 claims 1
- 230000001667 episodic effect Effects 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 208000013403 hyperactivity Diseases 0.000 claims 1
- 201000003995 melancholia Diseases 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 239000003595 mist Substances 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- ZBWSBXGHYDWMAK-UHFFFAOYSA-N psilocin Chemical compound C1=CC=C(O)[C]2C(CCN(C)C)=CN=C21 ZBWSBXGHYDWMAK-UHFFFAOYSA-N 0.000 claims 1
- QKTAAWLCLHMUTJ-UHFFFAOYSA-N psilocybin Chemical compound C1C=CC(OP(O)(O)=O)=C2C(CCN(C)C)=CN=C21 QKTAAWLCLHMUTJ-UHFFFAOYSA-N 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 231100000872 sexual dysfunction Toxicity 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 125000005415 substituted alkoxy group Chemical group 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063086830P | 2020-10-02 | 2020-10-02 | |
| US63/086,830 | 2020-10-02 | ||
| US202063114769P | 2020-11-17 | 2020-11-17 | |
| US63/114,769 | 2020-11-17 | ||
| US202163241891P | 2021-09-08 | 2021-09-08 | |
| US63/241,891 | 2021-09-08 | ||
| PCT/EP2021/077057 WO2022069690A2 (en) | 2020-10-02 | 2021-10-01 | Methods for delivery of psychedelic medications by inhalation and systems for performing the methods |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023544724A JP2023544724A (ja) | 2023-10-25 |
| JPWO2022069690A5 true JPWO2022069690A5 (https=) | 2024-07-29 |
| JP2023544724A5 JP2023544724A5 (https=) | 2024-07-29 |
Family
ID=78080292
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023519831A Pending JP2023544724A (ja) | 2020-10-02 | 2021-10-01 | 吸入による幻覚発動薬の送達方法および方法を実施するためのシステム |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230355583A1 (https=) |
| EP (1) | EP4221682A2 (https=) |
| JP (1) | JP2023544724A (https=) |
| KR (1) | KR20230079351A (https=) |
| AU (1) | AU2021354006A1 (https=) |
| CA (1) | CA3194558A1 (https=) |
| WO (1) | WO2022069690A2 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201907871D0 (en) | 2019-06-03 | 2019-07-17 | Small Pharma Ltd | Therapeutic compositions |
| CN114787363A (zh) | 2019-10-01 | 2022-07-22 | 恩派瑞安神经科学公司 | 对真菌进行遗传工程化以调节色胺表达 |
| JP7422473B2 (ja) | 2019-11-07 | 2024-01-26 | サイビン ユーケー リミテッド | 合成方法 |
| KR20240096817A (ko) | 2020-05-19 | 2024-06-26 | 사이빈 아이알엘 리미티드 | 중수소화된 트립타민 유도체 및 사용 방법 |
| US11773062B2 (en) | 2021-03-22 | 2023-10-03 | Small Pharma Ltd | Deuterated compounds |
| US12042564B2 (en) | 2020-06-02 | 2024-07-23 | Cybin Uk Ltd | Therapeutic solid dosage forms |
| US12122741B2 (en) | 2020-08-18 | 2024-10-22 | Cybin Irl Limited | Therapeutic phenethylamine compositions and methods of use |
| US11406619B2 (en) | 2020-08-28 | 2022-08-09 | Small Pharma Ltd | Injectable formulations |
| US12521370B2 (en) | 2020-12-01 | 2026-01-13 | Cybin Uk Ltd | Inhalable formulations |
| US11660289B2 (en) | 2020-12-01 | 2023-05-30 | Small Pharma Ltd. | Deuterated or partially deuterated N,N-dimethyltryptamine compounds |
| US12492178B2 (en) | 2021-09-01 | 2025-12-09 | Empathbio, Inc. | Stable polymorph of R-MDMA HCl |
| US11697638B2 (en) | 2021-09-08 | 2023-07-11 | Small Pharma Ltd | 5-methoxy-N,N-dimethyltryptamine crystalline forms |
| US12318477B2 (en) | 2021-11-18 | 2025-06-03 | Cybin Uk Ltd | Injectable and inhalable formulations |
| US11912680B2 (en) | 2021-12-28 | 2024-02-27 | Empathbio, Inc. | Nitric oxide releasing prodrugs of MDA and MDMA |
| EP4457336A4 (en) | 2021-12-31 | 2026-01-14 | Empyrean Neuroscience Inc | ORGANISMS GENETICALLY MODIFIED TO PRODUCE PSYCHOTROPIC ALKALOIDS |
| US20250051279A1 (en) * | 2022-01-14 | 2025-02-13 | Cybin Irl Limited | Tryptamine compositions and methods |
| WO2023168023A1 (en) | 2022-03-04 | 2023-09-07 | Reset Pharmaceuticals, Inc. | Co-crystals or salts comprising psilocin |
| AU2023246690A1 (en) * | 2022-03-31 | 2024-11-07 | Cybin Irl Limited | Methods for delivery of psychedelic medications by inhalation and systems for performing the methods |
| CN120344243A (zh) * | 2022-10-13 | 2025-07-18 | 赛本英国有限公司 | 包含致幻剂的胃肠外制剂的施用方法 |
| EP4601638A2 (en) * | 2022-10-14 | 2025-08-20 | ATAI Therapeutics, Inc. | Acetal, ketal, and hemiaminal analogs of psilocin, processes for the preparation thereof, and methods of use |
| US12280216B2 (en) | 2023-02-01 | 2025-04-22 | Thomas E. Garrison | Mixtures including nitrous oxide |
| US11980717B1 (en) * | 2023-02-01 | 2024-05-14 | Thomas E. Garrison | Mixtures including nitrous oxide |
| WO2025010308A2 (en) * | 2023-07-03 | 2025-01-09 | Empathbio, Inc. | Mdma enantiomer compositions and methods for modulating aggression response |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7267121B2 (en) | 2004-04-20 | 2007-09-11 | Aerogen, Inc. | Aerosol delivery apparatus and method for pressure-assisted breathing systems |
| CN104906669A (zh) * | 2007-03-30 | 2015-09-16 | 菲利普莫里斯生产公司 | 用于输送药剂的装置和方法 |
| MA50786A (fr) * | 2017-10-26 | 2022-04-27 | Blumentech S L | Produit d'association pour le traitement de troubles neurologiques et/ou psychiatriques |
| EP4353314A3 (en) * | 2019-02-22 | 2024-07-03 | GH Research Ireland Limited | 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) for treating major depression |
| RU199823U1 (ru) | 2020-06-10 | 2020-09-21 | Общество С Ограниченной Ответственностью "Центр Передовых Радиационных Медицинских И Биологических Технологий | Устройство для лечения бронхолегочных заболеваний |
-
2021
- 2021-10-01 JP JP2023519831A patent/JP2023544724A/ja active Pending
- 2021-10-01 CA CA3194558A patent/CA3194558A1/en active Pending
- 2021-10-01 WO PCT/EP2021/077057 patent/WO2022069690A2/en not_active Ceased
- 2021-10-01 EP EP21786852.0A patent/EP4221682A2/en active Pending
- 2021-10-01 AU AU2021354006A patent/AU2021354006A1/en active Pending
- 2021-10-01 US US18/027,810 patent/US20230355583A1/en active Pending
- 2021-10-01 KR KR1020237007858A patent/KR20230079351A/ko active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2022069690A5 (https=) | ||
| JP2023544724A (ja) | 吸入による幻覚発動薬の送達方法および方法を実施するためのシステム | |
| CN102264703B (zh) | 作为β2肾上腺素受体促效剂的5-(2-{[6-(2,2-二氟-2-苯基乙氧基)己基]氨基}-1-羟乙基)-8-羟基喹啉-2(1H)-酮的甲磺酸盐 | |
| JP2001513492A (ja) | 生物活性巨大分子を含む水性エアゾール製剤及び該エアゾールの製造方法 | |
| JP4537652B2 (ja) | 抗コリン作用薬及びシクレソニドをベースとする新規薬剤組成物 | |
| TWI758617B (zh) | 包含格隆銨鹽及茚達特羅鹽的氣霧劑藥物組合物、其製備方法與用途 | |
| ES2315425T3 (es) | Compuestos de amonio cuaternario y su uso como agentes antimuscarinicos. | |
| CN1289086C (zh) | 抗疟治疗药物的新用途 | |
| CA2952701C (en) | Muscarinic antagonists and combinations thereof for the treatment of airway disease in horses | |
| KR20240052775A (ko) | 병용 약물 요법 | |
| CN1649588A (zh) | 基于抗胆碱能药物及pde－iv抑制剂的新颖药物组合物 | |
| RU2008124833A (ru) | Лечение астмы и хронического обструктивного заболевания легких с использованием тройных комбинаций | |
| WO2023186963A1 (en) | Combination of nitrous oxide and 5-ht2a receptor agonists | |
| TW200536533A (en) | Organic compounds | |
| WO2021230340A1 (ja) | 新規吸入剤 | |
| CA2588042A1 (en) | Compositions and methods for pulmonary conditions | |
| TW201031408A (en) | Novel methods | |
| JP2007523119A (ja) | ベンジル酸エステル及び可溶性ｔｎｆ受容体融合タンパク質を基にした新規な医薬組成物 | |
| RU2008124838A (ru) | Органические соединения | |
| JP2005505560A (ja) | 三環系５，６−ジヒドロ−９Ｈ−ピラゾロ（３，４−ｃ）−１，２，４−トリアゾロ（４，３−アルファ）ピリジンを含む吸入組成物 | |
| KR20240134951A (ko) | 트립타민 조성물 및 방법 | |
| MXPA05004584A (es) | Compuestos de amonio cuaternario. | |
| EA012583B1 (ru) | КОМПОЗИЦИЯ ДЛЯ АЭРОЗОЛЬНОЙ ИНГАЛЯЦИИ β-АГОНИСТОВ | |
| JP2007524699A (ja) | ロフルミラストとグリコピロニウムとの組合せ物 | |
| US20250205198A1 (en) | Methods for delivery of psychedelic medications by inhalation and systems for performing the methods |